Bessemer Group
RXRX icon

Bessemer Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Bessemer Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-324
Closed -$2K – 2689
2025
Q3 		$2K Buy
+324
New +$1.7K ﹤0.01% 2347
2024
Q4 		– Sell
-185
Closed -$1K – 2659
2024
Q3 		$1K Buy
+185
New +$1.33K ﹤0.01% 2525

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bessemer Group's RXRX Position: Q4 2025 in Review

Bessemer Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 324 shares — an estimated $2K sold.

Bessemer Group first reported a position in RXRX in Q3 2024 and held it in 2 quarters. The position peaked at $2K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Bessemer Group reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bessemer Group sold 324 Recursion Pharmaceuticals shares in Q4 2025, an estimated $2K.
  • Bessemer Group first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Bessemer Group's Recursion Pharmaceuticals position peaked at $2K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.